Syngen BiotechLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Syngen BiotechLtd şirketinin toplam hissedar öz sermayesi NT$2.2B ve toplam borcu NT$237.7M olup, bu da borç-öz sermaye oranını 10.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$3.0B ve NT$818.7M dir. Syngen BiotechLtd 'in FAVÖK'ü NT$305.1M faiz karşılama oranı 40.9 dur. Şirketin NT$228.3M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

10.9%

Borç/özkaynak oranı

NT$237.73m

Borç

Faiz karşılama oranı	40.9x
Nakit	NT$228.31m
Eşitlik	NT$2.18b
Toplam yükümlülükler	NT$818.68m
Toplam varlıklar	NT$3.00b

Son finansal sağlık güncellemeleri

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Mar 25

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Recent updates

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

Jan 14

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Dec 16

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Nov 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 8279 'nin kısa vadeli varlıkları ( NT$1.0B ) kısa vadeli yükümlülüklerini ( NT$471.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 8279 şirketinin kısa vadeli varlıkları ( NT$1.0B ) uzun vadeli yükümlülüklerini ( NT$346.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 8279 'nin net borç/öz sermaye oranı ( 0.4% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: 8279 'nin borç/öz sermaye oranı son 5 yılda 17.5% seviyesinden 10.9% seviyesine düştü.

Borç Kapsamı: 8279 'nin borcu işletme nakit akışı ( 143.8% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: 8279 'in borcuna ilişkin faiz ödemeleri EBIT ( 40.9 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Syngen BiotechLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Recent updates

Third quarter 2024 earnings released: EPS: NT$2.67 (vs NT$2.59 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$1.83 (vs NT$2.76 in 2Q 2023)

Investor sentiment deteriorates as stock falls 18%

Upcoming dividend of NT$5.00 per share

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2023 earnings: EPS exceeds analyst expectations

Syngen Biotech Co.,Ltd., Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: EPS: NT$2.59 (vs NT$3.37 in 3Q 2022)

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of NT$5.00 per share at 2.9% yield

Full year 2022 earnings released: EPS: NT$11.85 (vs NT$8.77 in FY 2021)

No independent directors

Third quarter 2022 earnings released: EPS: NT$3.37 (vs NT$2.54 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$4.00 per share

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

No independent directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS NT$2.54 (vs NT$2.20 in 3Q 2020)

Upcoming dividend of NT$3.50 per share

Second quarter 2021 earnings released: EPS NT$2.25 (vs NT$2.75 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$1.53 (vs NT$1.48 in 1Q 2020)

Does Syngen BiotechLtd (GTSM:8279) Have A Healthy Balance Sheet?

Full year 2020 earnings released: EPS NT$7.95 (vs NT$7.86 in FY 2019)

Syngen Biotech Co., Ltd., Annual General Meeting, May 28, 2021

New 90-day high: NT$113

Should Syngen Biotech Co., Ltd. (GTSM:8279) Be Part Of Your Dividend Portfolio?

Did You Miss Syngen Biotech's (GTSM:8279) Impressive 104% Share Price Gain?

Is Syngen Biotech Co., Ltd.'s (GTSM:8279) Latest Stock Performance Being Led By Its Strong Fundamentals?

New 90-day low: NT$107

Syngen Biotech (GTSM:8279) Seems To Use Debt Quite Sensibly

Syngen Biotech's (GTSM:8279) Earnings Are Growing But Is There More To The Story?

Third quarter earnings released

New 90-day low: NT$107

First half earnings released

New 90-day high - NT$130

First half earnings released

New 90-day high - NT$120

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin